| 12/03/19 | 07:00:04 | 12 Mar 2019 | | Sareum Holdings PLC Issue of Options | RNS |
| 04/03/19 | 07:00:06 | 4 Mar 2019 | | HALF-YEARLY RESULTS ENDED 31 DECEMBER 2018 | RNS |
| 28/02/19 | 14:04:38 | 28 Feb 2019 | | Sierra Oncology has reported its 2018 Results | RNS |
| 28/02/19 | 08:14:44 | 28 Feb 2019 | | New SRA737 preclin data to be presented at AACR | RNS |
| 23/01/19 | 13:38:33 | 23 Jan 2019 | | Sierra Oncology to present SRA737 at DDR Tx Summit | RNS |
| 18/12/18 | 12:35:40 | 18 Dec 2018 | | Results of AGM | RNS |
| 18/12/18 | 07:00:03 | 18 Dec 2018 | | AGM Statement | RNS |
| 30/11/18 | 11:17:54 | 30 Nov 2018 | | Amendment to Preclinical Efficacy Announcement | RNS |
| 30/11/18 | 07:45:05 | 30 Nov 2018 | | Preclinical Efficacy for Immunotherapy Combination | RNS |
| 15/11/18 | 10:24:27 | 15 Nov 2018 | | Preclinical Data for SRA737 in Ovarian Cancer | RNS |
| 14/11/18 | 07:00:04 | 14 Nov 2018 | | AGM NOTICE | RNS |
| 13/11/18 | 07:00:19 | 13 Nov 2018 | | Directorate Change | RNS |
| 08/11/18 | 12:28:00 | 8 Nov 2018 | | Sierra Oncology Q3 2018 Results | RNS |
| 26/10/18 | 08:00:03 | 26 Oct 2018 | | Completion of Placing | RNS |
| 01/10/18 | 08:00:04 | 1 Oct 2018 | | FINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018 | RNS |
| 27/09/18 | 14:03:16 | 27 Sept 2018 | | Notice of Results | RNS |
| 26/09/18 | 08:00:03 | 26 Sept 2018 | | TYK2/JAK1 selected for certain cancers | RNS |
| 11/09/18 | 08:00:09 | 11 Sept 2018 | | Pre-Close Trading Statement | RNS |
| 10/09/18 | 08:00:04 | 10 Sept 2018 | | Selection of TYK2/JAK1 for autoimmune diseases | RNS |
| 09/08/18 | 14:15:21 | 9 Aug 2018 | | Sareum notes Sierra Oncology Q2 2018 Results | RNS |
| 11/07/18 | 10:38:39 | 11 Jul 2018 | | Notification of PCA Shareholding | RNS |
| 15/06/18 | 08:00:06 | 15 Jun 2018 | | Advisers | RNS |
| 31/05/18 | 08:00:02 | 31 May 2018 | | Sareum regains rights to Aurora+FLT3 inhibitors | RNS |
| 10/05/18 | 13:21:19 | 10 May 2018 | | SRA737 trial update in Sierra Oncology Q1 Results | RNS |
| 24/04/18 | 08:00:08 | 24 Apr 2018 | | Sareum to Present at BioTrinity 2018 in London | RNS |
| 17/04/18 | 13:45:47 | 17 Apr 2018 | | AACR 2018 Update | RNS |
| 15/03/18 | 07:00:06 | 15 Mar 2018 | | Late-breaker abstract for SRA737 accepted for AACR | RNS |
| 13/03/18 | 07:00:02 | 13 Mar 2018 | | Interim Results | RNS |
| 27/02/18 | 12:50:17 | 27 Feb 2018 | | Sierra Oncology expands SRA737 development program | RNS |
| 22/02/18 | 07:00:08 | 22 Feb 2018 | | Preclinical synergy of sra737 and PARP inhibitor | RNS |
| 13/02/18 | 07:00:04 | 13 Feb 2018 | | Notice of Interim Results | RNS |
| 20/12/17 | 11:00:02 | 20 Dec 2017 | | Issue of Options | RNS |
| 19/12/17 | 07:00:05 | 19 Dec 2017 | | Patent Grants in Japan & China for TYK2 Inhibitors | RNS |
| 14/12/17 | 11:01:24 | 14 Dec 2017 | | Result of AGM | RNS |
| 14/12/17 | 07:00:02 | 14 Dec 2017 | | AGM Statement | RNS |
| 20/11/17 | 07:00:06 | 20 Nov 2017 | | Notice of AGM and Annual Report & Accounts | RNS |
| 14/11/17 | 12:05:24 | 14 Nov 2017 | | Placing | RNS |
| 31/10/17 | 07:00:05 | 31 Oct 2017 | | Sierra Reports Preclinical Data for Chk1 Inhibitor | RNS |
| 19/10/17 | 08:00:02 | 19 Oct 2017 | | Final Results | RNS |
| 09/10/17 | 13:00:01 | 9 Oct 2017 | | Sierra Oncology host KOL Meeting on 12 Oct in NY | RNS |
| 18/09/17 | 13:00:02 | 18 Sept 2017 | | Sierra Oncology to host call on Chk1 inhibitor | RNS |
| 22/08/17 | 08:00:02 | 22 Aug 2017 | | Pre-Close Trading Statement | RNS |
| 19/06/17 | 08:00:05 | 19 Jun 2017 | | Sareum to Present at the ICCS 2017 | RNS |
| 05/06/17 | 13:13:15 | 5 Jun 2017 | | Chk1 Clinical Trials Update | RNS |
| 31/05/17 | 08:00:06 | 31 May 2017 | | Sierra Oncology Granted US and EU Patents | RNS |
| 25/05/17 | 08:00:13 | 25 May 2017 | | Sierra Oncology to Present at ASCO Annual Meeting | RNS |
| 09/05/17 | 08:00:09 | 9 May 2017 | | Sareum to Present at BioTrinity 2017 | RNS |
| 09/03/17 | 07:00:19 | 9 Mar 2017 | | Director Shareholding | RNS |
| 20/02/17 | 07:00:10 | 20 Feb 2017 | | Half-year Results | RNS |
| 09/02/17 | 07:00:10 | 9 Feb 2017 | | Notice of Interim Results | RNS |
